Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

2.
3.

Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.

[No authors listed]

Diabetologia. 1996 Dec;39(12):1554-61. Erratum in: Diabetologia 1997 Mar;40(3):366.

PMID:
8960842
4.

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group..

Arch Ophthalmol. 2004 Nov;122(11):1631-40.

PMID:
15534123
5.

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).

Gray A, Clarke P, Raikou M, Adler A, Stevens R, Neil A, Cull C, Stratton I, Holman R; UKPDS Group..

Diabet Med. 2001 Jun;18(6):438-44.

PMID:
11472461
7.

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.

Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD.

Diabetes Care. 2000 Jul;23(7):888-92.

8.

Controversies surrounding the treatment of the hypertensive patient with diabetes.

Prisant LM, Louard RJ.

Curr Hypertens Rep. 1999 Dec;1(6):512-20.

PMID:
10981115
9.

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR.

N Engl J Med. 2008 Oct 9;359(15):1565-76. doi: 10.1056/NEJMoa0806359. Epub 2008 Sep 10.

10.

Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.

Holzgreve H, Nakov R, Beck K, Janka HU.

Am J Hypertens. 2003 May;16(5 Pt 1):381-6.

PMID:
12745200
12.

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.

Nielsen FS, Rossing P, Gall MA, Skøtt P, Smidt UM, Parving HH.

Diabetes. 1997 Jul;46(7):1182-8.

PMID:
9200654
13.

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR.

BMJ. 2000 Aug 12;321(7258):412-9.

14.

Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.

Nielsen FS, Rossing P, Gall MA, Smidt UM, Chen JW, Sato A, Parving HH.

Scand J Clin Lab Invest. 1997 Aug;57(5):427-34.

PMID:
9279969
15.

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE.

Lancet. 1999 Feb 20;353(9153):611-6.

PMID:
10030325
16.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

17.

Diabetes guidelines: easier to preach than to practise?

Bryant W, Greenfield JR, Chisholm DJ, Campbell LV.

Med J Aust. 2006 Sep 18;185(6):305-9.

PMID:
16999670
20.

Are angiotensin-converting enzyme inhibitors the best treatment for hypertension in type 2 diabetes?

Komers R, Anderson S.

Curr Opin Nephrol Hypertens. 2000 Mar;9(2):173-9. Review.

PMID:
10757223

Supplemental Content

Support Center